Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $214,560.38 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis sold 466 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $214,560.38. Following the completion of the sale, the executive vice president owned 51,436 shares in the company, valued at approximately $23,682,677.48. This represents a 0.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ourania Tatsis also recently made the following trade(s):

• On Wednesday, January 7th, Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $474.99, for a total transaction of $2,137,455.00.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $491.47 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.68. The company’s fifty day moving average price is $459.98 and its 200 day moving average price is $427.48. The company has a market capitalization of $124.70 billion, a PE ratio of 32.06 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The firm had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.90% and a net margin of 32.94%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.98 earnings per share. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC boosted its stake in Vertex Pharmaceuticals by 0.3% during the fourth quarter. Kestra Advisory Services LLC now owns 14,431 shares of the pharmaceutical company’s stock worth $6,542,000 after buying an additional 40 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in shares of Vertex Pharmaceuticals by 44.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,002 shares of the pharmaceutical company’s stock valued at $454,000 after acquiring an additional 308 shares during the last quarter. 1248 Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 4.8% in the fourth quarter. 1248 Management LLC now owns 1,343 shares of the pharmaceutical company’s stock valued at $609,000 after purchasing an additional 62 shares during the period. The Manufacturers Life Insurance Company increased its position in Vertex Pharmaceuticals by 9.3% during the fourth quarter. The Manufacturers Life Insurance Company now owns 557,713 shares of the pharmaceutical company’s stock worth $252,880,000 after purchasing an additional 47,548 shares during the last quarter. Finally, Wimmer Associates 1 LLC increased its position in Vertex Pharmaceuticals by 1.3% during the fourth quarter. Wimmer Associates 1 LLC now owns 5,526 shares of the pharmaceutical company’s stock worth $2,505,000 after purchasing an additional 71 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on VRTX. Scotiabank lifted their target price on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday. UBS Group boosted their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Stifel Nicolaus increased their target price on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a report on Friday. Oppenheimer raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price target on the stock in a research note on Friday. Finally, Leerink Partners boosted their price target on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research report on Monday, December 29th. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $537.05.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.